Related Experiment Video
Updated: Sep 8, 2025
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
9.9K
Four New Coumarins From Calophyllum membranaceum With CYP Family 1 Enzymes Inhibitory Activity
Ting-Ting Cao1,2, Fu-Qiang Song1, Ping-Jing Yu1
1School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology of Natural Products, Kunming Medical University, Kunming, Yunnan, P. R. China.
Chemistry & Biodiversity
|August 21, 2025
Summary
Researchers identified new coumarins from Calophyllum membranaceum, with two showing significant activity against CYP1B1 and CYP1A1 enzymes. These compounds may aid in developing targeted antitumor drugs.
Area of Science:
- Natural Product Chemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Calophyllum species are a rich source of bioactive compounds.
- Coumarins are known for diverse pharmacological activities.
- Cytochrome P450 (CYP) enzymes play crucial roles in drug metabolism and disease pathways.
Purpose of the Study:
- To isolate and characterize new coumarins from Calophyllum membranaceum.
- To evaluate the inhibitory effects of isolated coumarins on CYP family 1 enzymes.
- To explore the potential of these compounds as antitumor drug leads.
Main Methods:
- Phytochemical investigation using spectroscopic and spectrometric analyses.
- Structure elucidation aided by computational studies.
- In vitro enzyme inhibition assays for CYP1A1 and CYP1B1.
Main Results:
- Four new coumarins (calomembolides G-J) and three known coumarins were isolated.
- Compound 4 showed 79.11% ± 12.95% inhibition of CYP1B1.
- Compound 6 exhibited 29.95% ± 8.09% inhibition of CYP1A1.
Conclusions:
- Calophyllum membranaceum is a source of novel coumarins with potential therapeutic applications.
- Compounds 4 and 6 demonstrate selective inhibition of CYP1B1 and CYP1A1, respectively.
- These findings provide a basis for developing targeted antitumor therapies.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:16Calmodulin-dependent Signaling
5.3K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.3K
01:30Enzyme Inhibition
79.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
79.5K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
984
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
984
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
671
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
671